Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740771 | 0.89 | RECQL (0.53) | RECQLHTTRAB9AMEN1KMT2A | |
| SCHEMBL7144170 | 0.84 | RECQL (0.43) | RECQLHTTRAB9AMEN1KMT2A | |
| SCHEMBL5563257 | 0.84 | RECQL (0.43) | RECQLHTTRAB9AMEN1KMT2A | |
| SCHEMBL31217344 | 0.82 | RECQL (0.43) | RECQLHTTRAB9AMEN1KMT2A | |
| SCHEMBL31554175 | 0.82 | PDGFRB (0.52) | RECQLHTTMEN1KMT2AMAPT | |
| SCHEMBL5557383 | 0.82 | LMNA (0.43) | RECQLHTTMAPTTP53SMN1; SMN2 | |
| SCHEMBL12072957 | 0.82 | LCK (0.41) | HTTRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5557182 | 0.82 | RECQL (0.43) | RECQLHTTRAB9AMEN1KMT2A | |
| SCHEMBL28355220 | 0.81 | AAK1 (0.41) | HTTRAB9AMEN1KMT2AMAPT | |
| SCHEMBL5953011 | 0.80 | MAPT (0.51) | RECQLHTTRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122340-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON DERIVATIVES OF TRICYCLIC POLYHYDROACRIDINE AND ANALOGS POSSESSING FUSED SATURATED FIVE-AND-SEVEN-MEMBERED RINGS | QUIMATRYX S L (ES) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122340-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON DERIVATIVES OF TRICYCLIC POLYHYDROACRIDINE AND ANALOGS POSSESSING FUSED SATURATED FIVE-AND-SEVEN-MEMBERED RINGS | HDAC5, HDAC1, HDAC7 | RECQL 676/4885HTT 249/4885RAB9A 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.